White Paper Highlights and Key Takeaways
Next-best action’s customer-centric history and the new opportunities created by de-identified patient data
How AI maximizes next-best action in pharma’s impact by identifying the windows in time when brand-eligible patients are expected to see their HCPs
Current next-best-action approaches using physician-level data – and what’s missing
Incredible patient-first research results and real-world pharma advertising case studies
Results that Surpass Today’s HCP Marketing Approaches
The white paper includes the results of a study OptimizeRx conducted on the performance of 60+ programs run on our patient-first, AI-enabled omnichannel platform, as well as case studies of two major multinational pharma manufacturers.
Learn why nothing is more actionable than knowing the windows in time when patients are meeting with their HCPs – and which patient-first best practices achieve 28% higher script impact.
